CMV Treatment Guidelines

Introduction to CMV Treatment

The National Comprehensive Cancer Network recommends oral valganciclovir should be initiated after 3-5 days of intravenous ganciclovir therapy once clinical improvement is observed and adequate oral absorption can be assured 1, 2, 3

The National Comprehensive Cancer Network suggests starting with intravenous ganciclovir 5 mg/kg twice daily for initial treatment of CMV infection, and continuing IV therapy for 3-5 days to rapidly achieve therapeutic levels 2, 3
Clinical improvement should be monitored (reduced symptoms, improved laboratory parameters) during this period 2, 3

Switch to oral valganciclovir when clinical improvement is observed after 3-5 days of IV therapy, and adequate gastrointestinal absorption is assured (no significant GI symptoms that would impair absorption) 2, 3
The National Comprehensive Cancer Network recommends no severe gastrointestinal GVHD (grades 3-4) in transplant patients before switching to oral therapy 1

For CMV retinitis, the Centers for Disease Control and Prevention recommends oral valganciclovir alone may be adequate from the start for small peripheral lesions, but for sight-threatening lesions (near optic nerve or fovea), consider intraocular implant plus valganciclovir 1, 5, 6
Treatment should continue until immune recovery (CD4+ count >100 cells/μL for 3-6 months in HIV patients) 5, 7

The Centers for Disease Control and Prevention suggests weekly monitoring of CMV viral load by PCR or pp65 antigenemia 8
Regular monitoring of complete blood count due to risk of myelosuppression, and renal function should be monitored regularly 4
For CMV retinitis, regular ophthalmologic examinations are recommended 4
Continue treatment until CMV is no longer detectable by plasma NAT or pp65 antigenemia 8, 9

The National Comprehensive Cancer Network warns against switching to oral therapy too early in patients with severe disease or questionable GI absorption 2
Inadequate dose adjustment in patients with renal impairment should be avoided 4
Failure to monitor for neutropenia, which may require dose reduction or temporary discontinuation, is a common pitfall 4
Premature discontinuation of therapy before viral clearance should be avoided 8, 9
Not considering hepatic function when using valganciclovir in liver transplant patients (bioabsorption may occur but decreased conversion to active form) is another pitfall 1